Chlorfenson

Identification

Generic Name
Chlorfenson
DrugBank Accession Number
DB05377
Background

Chlorfenson is developed by Moberg Derma for the treatment of onychomycosis (nail fungus) as the primary indication.

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 303.161
Monoisotopic: 301.957120226
Chemical Formula
C12H8Cl2O3S
Synonyms
  • 4-Chlorophenyl 4-chlorobenzenesulfonate
  • Ester sulfonate
External IDs
  • K-101
  • K101

Pharmacology

Indication

Investigated for use/treatment in fungal infections.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action

Chlorfenson is a topical solution applied once-daily on affected nails during treatment periods of 3-6 months. In pilot studies, Chlorfenson has shown promising results and provides important benefits compared to existing treatment alternatives. There is a significant need for more efficacious topical treatments. For more severe cases of the disease where more than 50% of the nail is affected, the only available options are oral anti-fungals which are associated with a certain risk for severe side effects.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as benzenesulfonate esters. These are arenesulfonate esters that result from the formal condensation of the hydroxy group of an alcohol, enol, phenol or heteroarenol with benzenesulfonic acid.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzenesulfonic acids and derivatives
Direct Parent
Benzenesulfonate esters
Alternative Parents
Benzenesulfonyl compounds / Arylsulfonic acids and derivatives / Phenoxy compounds / Chlorobenzenes / Organosulfonic acid esters / Aryl chlorides / Sulfonyls / Organooxygen compounds / Organochlorides / Organic oxides
show 1 more
Substituents
Aromatic homomonocyclic compound / Aryl chloride / Aryl halide / Arylsulfonic acid or derivatives / Benzenesulfonate ester / Benzenesulfonyl group / Chlorobenzene / Halobenzene / Hydrocarbon derivative / Organic oxide
show 10 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
arenesulfonic acid (CHEBI:82155) / Acaricides (C19024)
Affected organisms
Not Available

Chemical Identifiers

UNII
LW65NJ3YWV
CAS number
80-33-1
InChI Key
RZXLPPRPEOUENN-UHFFFAOYSA-N
InChI
InChI=1S/C12H8Cl2O3S/c13-9-1-5-11(6-2-9)17-18(15,16)12-7-3-10(14)4-8-12/h1-8H
IUPAC Name
4-chlorophenyl 4-chlorobenzene-1-sulfonate
SMILES
ClC1=CC=C(OS(=O)(=O)C2=CC=C(Cl)C=C2)C=C1

References

General References
Not Available
KEGG Compound
C19024
PubChem Compound
6635
PubChem Substance
175426986
ChemSpider
6383
ChEBI
82155
ChEMBL
CHEMBL499017
ZINC
ZINC000001687057

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0079 mg/mLALOGPS
logP3.5ALOGPS
logP4.4Chemaxon
logS-4.6ALOGPS
Physiological Charge0Chemaxon
Hydrogen Acceptor Count2Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area43.37 Å2Chemaxon
Rotatable Bond Count3Chemaxon
Refractivity70.55 m3·mol-1Chemaxon
Polarizability28.27 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9972
Blood Brain Barrier+0.9299
Caco-2 permeable-0.5725
P-glycoprotein substrateNon-substrate0.8546
P-glycoprotein inhibitor INon-inhibitor0.5869
P-glycoprotein inhibitor IINon-inhibitor0.9479
Renal organic cation transporterNon-inhibitor0.8245
CYP450 2C9 substrateNon-substrate0.7722
CYP450 2D6 substrateNon-substrate0.7774
CYP450 3A4 substrateNon-substrate0.5496
CYP450 1A2 substrateInhibitor0.7088
CYP450 2C9 inhibitorInhibitor0.5368
CYP450 2D6 inhibitorNon-inhibitor0.9031
CYP450 2C19 inhibitorInhibitor0.6912
CYP450 3A4 inhibitorNon-inhibitor0.8338
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5794
Ames testNon AMES toxic0.7203
CarcinogenicityCarcinogens 0.7705
BiodegradationNot ready biodegradable0.5426
Rat acute toxicity2.2681 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7591
hERG inhibition (predictor II)Non-inhibitor0.8301
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0udi-0109000000-ffeda6d7b9cbbf9ea338
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0udi-0009000000-8f6fb02831fbf334647e
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0udi-0209000000-e00578f8aea2c9aedd99
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-03di-9700000000-795113fccdc9ec72f9e7
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0udi-0039000000-b093cab87cc932542ad9
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0gza-9220000000-d754a7fae8fb6ed28dfe
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-157.8788238
predicted
DarkChem Lite v0.1.0
[M-H]-165.72707
predicted
DeepCCS 1.0 (2019)
[M+H]+158.9031238
predicted
DarkChem Lite v0.1.0
[M+H]+168.08505
predicted
DeepCCS 1.0 (2019)
[M+Na]+158.1782238
predicted
DarkChem Lite v0.1.0
[M+Na]+174.1782
predicted
DeepCCS 1.0 (2019)

Drug created at November 18, 2007 18:24 / Updated at June 12, 2020 16:52